<DOC>
	<DOCNO>NCT01208545</DOCNO>
	<brief_summary>The study hypothesis change serially obtain nerve conduction study data obtain every 3-4 week cancer patient receive chemotherapy use predict development clinically significant / disable drug induce neuropathy six twelve month follow start treatment . Patients breast cancer , colon cancer , gastroesophageal cancer , non-Hodgkins lymphoma enrol . Six low extremity nerve -- three leg -- electrically stimulated response record three four week interval coincide patient 's schedule chemotherapy .</brief_summary>
	<brief_title>Serial Electrophysiologic Monitoring During Administration Nerve-Toxic Chemotherapeutic Drugs</brief_title>
	<detailed_description />
	<mesh_term>Nerve Degeneration</mesh_term>
	<criteria>Clinical diagnosis untreated breast cancer , treat ( advance stage ) untreated colon cancer , untreated nonHodgkins lymphoma , advanced gastroesophageal cancer schedule begin chemotherapy either Taxol , oxaliplatin , vincristine Individuals implant electronic medical device ( cardiac pacemaker defibrillator , vagus nerve stimulator , deep brain stimulator , intrathecal pump , others ) Individuals whose chemotherapy regimen include nerve toxic drug Taxol , oxaliplatin , vincristine , include one three drug combination Individuals whose screen nerve conduction study show peroneal motor amplitude &lt; 1 mV bilaterally sural sensory amplitude &lt; 3 uV bilaterally result obtainable</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2010</verification_date>
	<keyword>taxol</keyword>
	<keyword>vincristine</keyword>
	<keyword>oxaliplatin</keyword>
	<keyword>chemotherapy</keyword>
	<keyword>nerve degeneration</keyword>
	<keyword>nerve conduction</keyword>
	<keyword>cancer</keyword>
	<keyword>nerve conduction study</keyword>
</DOC>